Table 4.
Comparison of CD4+ and CD8+ tumor-infiltrating lymphocyte infiltration in individual tumors
| Disease group | Hormone receptor status | CD4+ TIL > CD8+ TIL | CD4+ TIL < CD8+ TIL | CD4+ TIL = CD8+ TIL | p value |
|---|---|---|---|---|---|
| Pure DCIS | Total (n = 224) | 135 (60.3) | 88 (39.3) | 1 (0.4) | < 0.001 |
| HR positive (n = 196) | 116 (59.2) | 79 (40.3) | 1 (0.5) | < 0.001 | |
| HR negative (n = 28) | 19 (67.9) | 9 (32.1) | 0 (0.0) | 0.016 | |
| Invasive carcinoma | Total (n = 358) | 150 (41.9) | 208 (58.1) | 0 (0.0) | 0.006 |
| HR positive (n = 248) | 115 (46.4) | 133 (53.6) | 0 (0.0) | 0.580 | |
| HR negative (n = 110) | 35 (31.8) | 75 (68.2) | 0 (0.0) | < 0.001 |
p values were calculated by the Wilcoxon signed rank test. Data are presented as number of cases (%)
TIL tumor-infiltrating lymphocyte, DCIS ductal carcinoma in situ